
Celcuity (CELC) Stock Forecast & Price Target
Celcuity (CELC) Analyst Ratings
Bulls say
Celcuity is progressing rapidly towards commercialization and is poised for success with its differentiated drug candidate, gedatolisib, in both breast and prostate cancers. The recent positive results from its Phase 3 VIKTORIA-1 trial, along with ongoing trials and regulatory submissions, indicate a strong potential for market adoption and potential peak sales. With a well-funded balance sheet and experienced management team, Celcuity is a promising investment in the competitive landscape of cancer therapeutics.
Bears say
Celcuity is expected to face intense market competition with its gedatolisib drug, and a higher price point of $30,000 per cycle may limit its market potential. Additionally, there are various risk factors, including clinical, regulatory, and financial risks, that could negatively impact the company's share price. While recent updates and milestones have shown promise, the success of the drug and the company's ability to obtain necessary approvals and financing remain uncertain.
This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.
Celcuity (CELC) Analyst Forecast & Price Prediction
Start investing in Celcuity (CELC)
Order type
Buy in
Order amount
Est. shares
0 shares